Partial response and cardiovascular recovery after sorafenib dose reduction in a multinodular HCC patient

Journal of Gastrointestinal Cancer

Volumn 43, Issue SUPPL. 1, 2012, Pages

  Sacco, Rodolfo ^a,b   Bargellini, Irene ^a   Ginanni, Barbara ^a   Bertini, Marco ^a   Bozzi, Elena ^a   Altomare, Emanuele ^b   Battaglia, Valentina ^a   Romano, Antonio ^a   Tumino, Emanuele ^a   Di Biase, Matteo ^b   Bresci, Giampaolo ^a   Bartolozzi, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; CARVEDILOL; FUROSEMIDE; RAMIPRIL; SORAFENIB; ALANINE AMINOTRANSFERASE; IODINATED CONTRAST MEDIUM; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CHEMISTRY; CARDIOTOXICITY; CASE REPORT; CHEMOEMBOLIZATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE TRACT ENDOSCOPY; DRUG DOSE REDUCTION; DYSPNEA; ESOPHAGUS VARICES; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HUMAN; HYPOKINESIA; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT RESPONSE; VARICOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CARDIOVASCULAR EFFECT; CHILD PUGH SCORE; CONTRAST ENHANCEMENT; DRUG DOSE ESCALATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROCORTICOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; LUNG ANGIOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; COMPLICATION; DOSE RESPONSE; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS;

EID: 84875752307     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-011-9328-3     Document Type: Article

References (19)

1. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-7.
2. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6: 569-79.
3. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48: 964-70.
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
6. ChengAL,Kang YK, Chen Z, Tsao CJ, Qin S,KimJS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
7. Votrient EMA label. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/001141/WC500094272.pdf accessed 31 March 2011.
8. Sutent EMA label http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000687/WC500057737.pdf accessed 31 March 2011.
9. Nexavar FDA label. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2011/021923s011lbl.pdf accessed 31 March 2011.
10. Nexavar EMA label. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000690/WC500027704.pdf accessed 31 March 2011.
11. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol. 2011;22:1812-23.
12. Abou-Alfa G, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma. JAMA. 2010;304:2154-60.
13. Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67:751-64.
14. Snow H BA, Gelder M, Voliotis D, Kelley S: Sorafenib is not associated with a high incidence of cardiovascular events in many tumor types. Annals of Oncology 2008;19.
15. Valsuani C, Siclari O, Camerini A, Canale ML, Rondini M, Donati S, et al. Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases J. 2009;2:9133.
16. Kamada P, Dudek AZ. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Cancer Invest. 2010;28:501-4.
17. Wong MK, Jarkowski A. Response to sorafenib after sunitinibinduced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy. 2009;29:473-8.
18. Hilger RA, Richly H, Grubert M, Kredtke S, Thyssen D, Eberhardt W, et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther. 2009;47:61-4.
19. Vaziri SA, Kim J, Ganapathi MK, Ganapathi R. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep. 2010;12: 102-8.